All Cancers - One Solution

SMART-Phage™ for Truly Tumor-Specific Antibody Discovery

Partnering with biopharma to deliver tailored antibody solutions that drive therapeutic progress

All cancers share one feature:

Tn/STn antigens, abundant in tumors - absent in healthy cells

“Sucess starts with the right target” KOL

Healthy tissue

Tumor tissue

Combotopes' proprietary SMART-Phage™ Antibody Discovery Platform generates antibodies with:

DOI: https://doi.org/10.1038/s41589-025-01971-8

Tumor specificity

High affinity

Flexibility

It makes a difference

For Pharma:

Novel and revisited cancer targets
ADC, BsAb, BiTE, RIT, CART
Untouched IP space

For Patients:

Better treatment options
Reduced side-effects
Improved quality of life

We deliver:

Tumor-Selective & Target-Specific Antibodies with fast, cost-effective discovery and collaborative IP solutions

EGFR, VEGFR, HER2, CD37, FLT3, FGFR, CD19, CD22, CD27, CD25, CD30, CD33, CD38, CD43, Mesothelin, PD-L1, CD44, Podocalyxin (TRA1.60/80), CD133, CD90, CD326, Cripto-1, ABCG2, CD24, CD49, Notch2, CD146 (MUC18), CD10, CD117, CD26, CXCR4, CD34, CD271, CD13, CD56, CD105, LGR5, CD114, CD54, CXCR1, TIM-3, CD55, DLL-4, CD96, CD29, CD9, CD166, CD44, ABCB5, Notch3, CD123, MUC1, MUC4, MUC16, MUC17, MUC21, CD33, CD40, Claudin-18, Integrin alpha-3, CK7, CK20, CXCR2, CXCR4, Integrin alpha-5, CA9, EPCAM, MET, MMP14, DDR1, NRP1, LAMP1-4, CD99, ALCAM, SDC1, 2, 3, 4, Syndecans (1-4), ITA5, ROBO1, Nectin-4, Nectin-2, LRP1, CD70, Podoplanin, IGF-1R, ABCG2, IBT1, ALK, TEM1, HVEM, TERT, LYPD3, GPR56, IL6RA, DDR1, LIFR, GPR64, S1PR1-4, LRCHD2, NMB, Plexin1/2, PTHR, Semaphorins, Slit3, TACD2, VGFC, VLDLR, VTN

〰️

EGFR, VEGFR, HER2, CD37, FLT3, FGFR, CD19, CD22, CD27, CD25, CD30, CD33, CD38, CD43, Mesothelin, PD-L1, CD44, Podocalyxin (TRA1.60/80), CD133, CD90, CD326, Cripto-1, ABCG2, CD24, CD49, Notch2, CD146 (MUC18), CD10, CD117, CD26, CXCR4, CD34, CD271, CD13, CD56, CD105, LGR5, CD114, CD54, CXCR1, TIM-3, CD55, DLL-4, CD96, CD29, CD9, CD166, CD44, ABCB5, Notch3, CD123, MUC1, MUC4, MUC16, MUC17, MUC21, CD33, CD40, Claudin-18, Integrin alpha-3, CK7, CK20, CXCR2, CXCR4, Integrin alpha-5, CA9, EPCAM, MET, MMP14, DDR1, NRP1, LAMP1-4, CD99, ALCAM, SDC1, 2, 3, 4, Syndecans (1-4), ITA5, ROBO1, Nectin-4, Nectin-2, LRP1, CD70, Podoplanin, IGF-1R, ABCG2, IBT1, ALK, TEM1, HVEM, TERT, LYPD3, GPR56, IL6RA, DDR1, LIFR, GPR64, S1PR1-4, LRCHD2, NMB, Plexin1/2, PTHR, Semaphorins, Slit3, TACD2, VGFC, VLDLR, VTN 〰️

We offer an attractive win-win partnership business model

Upfront, and milestone payments tied to development and regulatory achievements
Royalties on product sales

Crystal structure revealing how Combotope antibodies specifically binds cancer-specific Tn-glycoprotein epitopes

Leadership

Dr. Klas Ola Blixt

CO-FOUNDER, INVENTOR, & CEO
Ola invented the SMART-Phage technology and is an expert in aberrant glycosylation and development of cancer-specific antibodies. With 20+ years in chemical biology and antibodies, he has an H-index of 50, multiple patents, and 15+ years of management experience.
Dr. Søren Nyboe Jakobsen

CO-FOUNDER, CSO
Søren is an inventor of key patents in molecular display and immune cell detection. He founded Tetramer Shop (acquired by 10x Genomics) and has led innovation at firms like Novo Nordisk, Nuevolution, and Immudex, with strong biotech startup leadership experience.

Newly Featured Target

Combotope Therapeutics ApS

Diplomvej 381

DK-2800 Kongens Lyngby

Denmark

Contact:

olablixt@combotope.com

Company registration (CVR) no. 44308266